{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:05:59Z","timestamp":1790269559818,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.parkreldis.2016.11.013","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T07:06:12Z","timestamp":1480489572000},"page":"S56-S60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"S1","title":["Apomorphine therapy in Parkinson's disease and future directions"],"prefix":"10.1016","volume":"33","author":[{"given":"Nataliya","family":"Titova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2016.11.013_bib1","first-page":"251","article-title":"Apomorphine in Parkinson's disease","volume":"56","author":"Schwab","year":"1951","journal-title":"Trans. Am. Neurol. Assoc."},{"issue":"8123","key":"10.1016\/j.parkreldis.2016.11.013_bib2","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0140-6736(79)91725-2","article-title":"Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease","volume":"1","author":"Corsini","year":"1979","journal-title":"Lancet"},{"issue":"Pt 2","key":"10.1016\/j.parkreldis.2016.11.013_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/brain\/107.2.487","article-title":"On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study","volume":"107","author":"Hardie","year":"1984","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.11.013_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(88)91193-2","article-title":"Subcutaneous apomorphine in parkinsonian on-off oscillations","volume":"8582","author":"Stibe","year":"1988","journal-title":"Lancet"},{"issue":"8622","key":"10.1016\/j.parkreldis.2016.11.013_bib5","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0140-6736(88)90860-4","article-title":"Subcutaneous apomorphine for on-off oscillations in Parkinson's disease","volume":"2","author":"Chaudhuri","year":"1988","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.013_bib6","first-page":"197","article-title":"Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect","volume":"1","author":"Martinez-Martin","year":"2011","journal-title":"J.\u00a0Park. Dis."},{"issue":"12","key":"10.1016\/j.parkreldis.2016.11.013_bib7","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.parkreldis.2013.08.012","article-title":"Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease","volume":"19","author":"Todorova","year":"2013","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2016.11.013_bib8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","article-title":"EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease","volume":"30","author":"Martinez-Martin","year":"2015","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.parkreldis.2016.11.013_bib9","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/ene.12091","article-title":"Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing \u2018off\u2019 periods in patients with established Parkinson's disease","volume":"20","author":"Grosset","year":"2013","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2016.11.013_bib10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/ane.12107","article-title":"Inhaled dry powder apomorphine (VR040) for \u2018off \u2019 periods in Parkinson's disease: an in-clinic double-blind dose ranging study","volume":"128","author":"Grosset","year":"2013","journal-title":"Acta. Neurol. Scand."},{"issue":"9","key":"10.1016\/j.parkreldis.2016.11.013_bib11","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/mds.26697","article-title":"Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease","volume":"31","author":"Hauser","year":"2016","journal-title":"Mov. Disord."},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2016.11.013_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ijpharm.2016.06.010","article-title":"Apomorphine and its esters: differences in Caco-2 cell permeability and chylomicron affinity","volume":"509","author":"Borkar","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.parkreldis.2016.11.013_bib13","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/mds.26626","article-title":"Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets","volume":"31","author":"Lincoln","year":"2016","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2016.11.013_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jconrel.2012.12.024","article-title":"PLGAs bearing carboxylated side chains: novel matrix formers with improved properties for controlled drug delivery","volume":"166","author":"Regnier-Delplace","year":"2013","journal-title":"J.\u00a0Control. Release"},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.013_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1353-8020(97)00009-6","article-title":"Use of apomorphine in parkinsonian patients with neuropsychiatric complications of oral treatment","volume":"3","author":"Ellis","year":"1997","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2016.11.013_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.parkreldis.2009.05.006","article-title":"Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations","volume":"16","author":"van Laar","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2016.11.013_bib17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1126\/science.347574","article-title":"Schizophrenic symptoms improve with apomorphine","volume":"200","author":"Tamminga","year":"1978","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.parkreldis.2016.11.013_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/brb3.115","article-title":"Dopamine-transporter levels drive striatal responses to apomorphine in Parkinson's disease","volume":"3","author":"Passamonti","year":"2013","journal-title":"Brain Behav."},{"issue":"1","key":"10.1016\/j.parkreldis.2016.11.013_bib19","first-page":"38","article-title":"The effect of age of onset of PD on risk of dementia","volume":"254","author":"Aarsland","year":"2007","journal-title":"J.\u00a0Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2016.11.013_bib20","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.nbd.2012.03.029","article-title":"Cognitive impairment and dementia in Parkinson's disease","volume":"46","author":"Pagonabarraga","year":"2012","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.013_bib21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.22319","article-title":"Apomorphine treatment in Alzheimer mice promoting amyloid-\u03b2 degradation","volume":"69","author":"Himeno","year":"2011","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.013_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ana.22359","article-title":"Apomorphine and Alzheimer A\u03b2: Roles for regulated \u03b1 cleavage, autophagy, and antioxidation?","volume":"69","author":"Steele","year":"2011","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.parkreldis.2016.11.013_bib23","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mds.26422","article-title":"Apomorphine: a potential modifier of amyloid deposition in Parkinson's disease?","volume":"31","author":"Yarnall","year":"2016","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2016.11.013_bib24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch. Neurol."},{"issue":"8","key":"10.1016\/j.parkreldis.2016.11.013_bib25","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/ene.13034","article-title":"EUROPAR and the IPMDS Non-Motor-PD-Study Group, A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists","volume":"23","author":"Rizos","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2016.11.013_bib26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/WNF.0000000000000091","article-title":"Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years' follow-up","volume":"38","author":"Todorova","year":"2015","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.013_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/mds.26099","article-title":"Management of impulse control disorders in Parkinson's disease: controversies and future approaches","volume":"30","author":"Samuel","year":"2015","journal-title":"Mov. Disord."},{"issue":"S1","key":"10.1016\/j.parkreldis.2016.11.013_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.parkreldis.2015.09.027","article-title":"Non motor subtypes and Parkinson's disease","volume":"22","author":"Sauerbier","year":"2016","journal-title":"Park. Relat. Disord."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016304588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016304588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T21:56:49Z","timestamp":1718920609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802016304588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":28,"alternative-id":["S1353802016304588"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.11.013","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apomorphine therapy in Parkinson's disease and future directions","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}